surmount-1 tirzepatide non-diabetic obesity weight loss 💊 Could a new medication help reduce complications of obesity? The SURMOUNT-MMO trial investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with or overweight but without diabetes. Researchers SURMOUNT Clinical Trials Orals Session

The SURPASSCVOT kidney analysis positions tirzepatide as a promising agent capable of delivering both metabolic and renal benefits beyond established GLP1 therapy

Heart Disease and Kidney Health Heart disease and chronic kidney disease (CKD) are closely connected, and having one condition may increase your risk for the other

i.e., weight maintenance and weight loss, in concomitance with a controlled intake of calories and improved physical activity, studies of three 68 weeks double-blind, placebo-controlled, randomized trials were conducted

doi: 10.1126/science.aau6977

Introducing Healthletic's BPC-157: A Closer Look A Clean, Oral Peptide Formulation for Modern Needs Healthletic's BPC-157 is designed for individuals seeking a trusted, high-quality peptide supplement that fits easily into a daily wellness routine

L-carnitina pulbere ofer 500mg per porie i se dizolv uor n ap sau shake, potrivit pentru cei care prefer s personalizeze buturile de antrenament